PubRank

Jörg Bäsecke

Author PubWeight™ 17.96‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011 3.43
2 Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011 2.72
3 Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012 1.96
4 Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012 1.85
5 Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008 1.41
6 Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 2011 1.40
7 The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 2010 1.18
8 Advances in targeting signal transduction pathways. Oncotarget 2012 1.06
9 Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle 2010 0.93
10 Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle 2010 0.91
11 Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Adv Enzyme Regul 2008 0.89
12 GSK-3beta is a critical mediator of tetrandrine induced cell cycle arrest and cytotoxicity. Cancer Biol Ther 2008 0.80
13 [Occlusion of the femoral arteries in de novo AML]. Med Klin (Munich) 2007 0.75
14 A case of pulmonary aspergillosis with lack of response to caspofungin. Rev Iberoam Micol 2006 0.75
15 [67-year old woman with long-standing microcytic anemia]. Dtsch Med Wochenschr 2016 0.75